Purpose: Evidence on the long-term impact of testicular cancer treatment on sexual function is not clear. Our aim was to estimate the effect of testicular cancer treatment on the risk of sexual dysfunction in long-term survivors of testicular cancer. Materials and Methods: We performed a cross-sectional study of 2,260 long-term survivors of testicular cancer with a median followup of 17 years (IQR 12e24), including 1,098 who underwent orchiectomy alone (surveillance), 788 treated with bleomycin, etoposide and cisplatin alone or post-chemotherapy retroperitoneal surgery, 300 treated with abdominal radiotherapy and 74 who received more than 1 line of treatment. Sexual function was evaluated by the IIEF-15 (International Index of Erectile Function-15) questionnaire. Results were compared between treatment groups using logistic regression analysis with the results on each of the 5 IIEF-15 dimensions as the outcome and treatment as exposure using surveillance as the referent. Results: The risk of erectile dysfunction was increased in all treatment groups compared to surveillance, including bleomycin, etoposide and cisplatin alone (OR 1.5, 95% CI 1.0e2.1, p <0.05), bleomycin, etoposide and cisplatin with postchemotherapy surgery (OR 2.1, 95% CI 1.4e3.4, p <0.005), radiotherapy (OR 1.7, 95% CI 1.1e2.5, p <0.05) and more than 1 line of treatment (OR 3.2, 95% CI 1.6e6.3, p <0.005). Orgasmic dysfunction was associated with radiotherapy, bleomycin, etoposide and cisplatin with post-chemotherapy surgery and more than 1 line of treatment. Conclusions: Treatment with bleomycin, etoposide and cisplatin, radiotherapy and more than 1 treatment line increased the risk of erectile dysfunction in longterm survivors of testicular cancer compared to surveillance. Patients should be informed about this as part of the information on treatment related late effects.
AS the majority of patients with TC become long-term survivors, 1 addressing patient reported late effects such as sexual dysfunction after TC treatment becomes increasingly important.
In a systematic review Nazareth et al reported a significantly increased risk of ejaculatory, orgasmic and erectile dysfunction up to 2 years after TC treatment. 2 It was emphasized that Accepted for publication April 24, 2018 . No direct or indirect commercial incentive associated with publishing this article.
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there is a lack of knowledge about how different treatment modalities (cisplatin based chemotherapy, abdominal radiotherapy and surgery) as well as psychological factors affect sexual function in TCSs. In a cross-sectional study from Norway Dahl et al found an increased risk of ejaculatory dysfunction in patients treated with retroperitoneal surgery and a possible association of cisplatin based chemotherapy and neurotoxicity with ejaculatory dysfunction among 1,084 TC survivors at a median followup of 11 years. 3 In a similarly designed study of 401 Danish long-term TCSs Rossen et al confirmed the association between retroperitoneal surgery and ejaculatory dysfunction while not confirming other associations between treatment modality and sexual dysfunction. 4 Thus, it is still unclear how current TC treatment, especially cisplatin based chemotherapy and abdominal radiotherapy, affects different aspects of sexual function in long-term TCSs.
We present data from a large nationwide and population based cross-sectional study of 2,572 longterm TCSs treated with the current standard of care. 5 The aims of the study were to 1) clarify the association between treatment modalities and different aspects of sexual function, and 2) investigate whether possible associations between treatment modalities and sexual function were mediated through psychological or physiological factors.
PATIENTS AND METHODS

Study Population
Between 2014 and 2016 we performed a questionnaire survey, DaTeCa-LATE (late treatment effects), evaluating patient reported outcomes in Danish TCSs with a median followup of 17 years after diagnosis. 5 All Danish TCSs included in the national DaTeCa database, including patients with TC treated from 1984 to 2007, 6 were invited. Of the 4,271 eligible TCSs 2,572 (60%) completed the 167-item questionnaire. Detailed information about the design of DaTeCa-LATE was previously reported. 5 Briefly, responders were older than nonresponders and in line with other studies more responders were in a relationship 7 while there was no difference in the Charlson comorbidity index between responders and nonresponders.
In the current study we excluded 71 responders (3%) with extragonadal germ cell cancer, 8 (0.3%) treated with high dose chemotherapy and bone marrow transplantation, and 233 (9%) with bilateral TC including contralateral germ cell neoplasia in situ, yielding a total of 2,260 TC survivors for analysis.
Treatment Protocol
Patients with stage I disease were treated with orchiectomy alone and followed on a surveillance program, except for some patients with large seminomas (6 cm or greater), who were offered adjuvant radiotherapy. 8 If there was primary disseminated disease or relapse, patients were initially treated with 3 or 4 courses of BEP. Those with small retroperitoneal seminomas (stage IIA) could be offered abdominal RT. In cases of residual disease after BEP surgical resection was performed.
In the current study TC survivors were divided into 5 treatment groups, including surveillance as the reference group, BEP with or without post-chemotherapy surgical resection of residual disease (BEP alone or BEP with postchemotherapy surgery), RT and MTOL as previously described.
9,10
Outcome Measures
All patients completed the IIEF-15 questionnaire, which covers erectile function (score 1 to 30), intercourse satisfaction (score 0 to 15), orgasmic function (score 1 to 10), sexual desire (score 2 to 10) and overall satisfaction (score 2 to 10). 11 A lower score on each of the 5 scales indicates a higher symptom burden. To evaluate erectile function and intercourse satisfaction only patients who reported having had sexual activity within the last 4 weeks were included. 4, 12 To evaluate neurotoxicity, which is a common side effect of cisplatin, patients completed the 11-item FACT/ GOG (Functional Assessment of Cancer Therapy/Gynecologic Oncology Group)-NTX (Neurotoxicity) subscale, version 4. 13 This questionnaire evaluates patient reported symptoms of neurotoxicity such as numbness, tingling or discomfort of hands and feet, and difficulty walking or buttoning buttons. In the current study we included the total neurotoxicity score, which ranges from 0 to 44 with a higher score indicating a higher symptom burden. We applied the HADS 14 to evaluate the influence of coexisting anxiety and depression. A score greater than 7 on each of the 2 scales (HADS-Anxiety and HADS-Depression) served as the cutoff value for caseness. 14 Some supplementary questions were asked regarding other factors with a possible influence on sexual function, including 1) the use of PDE5 inhibitors, 2) the use of testosterone substitution, 3) the patient assessment of the treatment influence on sexual function and 4) sexual activity during the last 4 weeks. The supplementary Appendix (http://jurology.com/) presents these items.
Information on marital status was obtained from the Danish Civil Registration System. 15 Information on comorbidity (Charlson comorbidity index excluding TC) as defined by Quan et al 16 was obtained from the DNPR (Danish National Patient Registry), which has registered the diagnoses of all patients admitted to hospitals since 1977. 15 The regional ethical committee of the Capital Region of Denmark approved the study (file No. H-2-2012-044).
Statistics
To evaluate erectile dysfunction we used a composite end point of an IIEF-Erectile Function score less than 22 12 or the use of PDE5 inhibitors. The composite end point was determined since erectile dysfunction is the primary indication of PDE5 inhibitor use. For the other 4 domains of the IIEF-15 a score in the lowest quartile was defined as the outcome. We constructed a logistic regression model with each of the 5 domains of the IIEF-15 scale as the outcome and the treatment, including BEP alone or with post-chemotherapy surgery, RT and MTOL vs surveillance as the reference group, as exposure was made to elucidate the effect of treatment on sexual function.
Further, to evaluate whether a treatment induced effect was mediated through physiological or psychological factors, adjustment was made for neurotoxicity (total neurotoxicity score in the FACT/GOG scale divided in quartiles), and anxiety and depression according to HADS. To adjust for other possible explanatory covariates additional adjustment was made for the Charlson comorbidity index (any comorbidity vs none) and tobacco consumption.
Finally, we constructed a logistic regression model with the patient reported negative impact of TC treatment on sexual function. The possible answers were dichotomized into a lot or very much vs very little, little or some. In this analysis only age adjustment was made.
Statistical analyses were performed in IBMÒ SPSSÒ Statistics for WindowsÒ, version 22.0.
RESULTS
A total of 2,260 TC survivors (60%) responded with complete questionnaires, including 1,098 in the surveillance group, 542 in the BEP alone group, 246 in the BEP with post-chemotherapy surgery group, 300 in the RT group, of whom 127 had received adjuvant RT, and 74 in the MTOL group. Across the entire cohort median followup was 17 years (IQR 12e24, supplementary table 1, http://jurology.com/). Supplementary table 1 (http://jurology.com/) lists additional information on body mass index, lifestyle factors and testosterone substitution.
The crude results of the IIEF-15 domains showed that 85% of patients on surveillance, 83% treated with BEP alone, 79% treated with BEP plus post-chemotherapy surgery, 76% treated with RT and 70% treated with MTOL had normal erectile function (supplementary table 2, http:// jurology.com/).
The age adjusted OR of erectile dysfunction was significantly increased in all treatment groups compared to surveillance (table 1). After adjusting for neurotoxicity the association between BEP alone and erectile dysfunction lost statistical significance. The association remained statistically significant after adjustment for additional explanatory variables in patients treated with BEP with postchemotherapy surgery, in the RT group and in the MTOL group.
The age adjusted OR of orgasmic dysfunction was significantly increased in all treatment groups except the group with BEP alone. After adjusting for neurotoxicity the effect was statistically significant only in the MTOL group.
Apart from RT consistently being associated with decreased overall satisfaction, there was no association between treatment modality and decreased overall satisfaction, decreased sexual desire or decreased intercourse satisfaction.
Anxiety, depression and neurotoxicity were significantly associated negatively with all aspects of sexual function. Likewise comorbidity was negatively associated with all aspects of sexual function except overall satisfaction (table 2) .
The self-rated negative impact of TC treatment on sexual function was significantly increased in all treatment groups compared to surveillance except in TC survivors who had been treated with BEP alone. The age adjusted OR was 1.4 (95% CI 0.9e2.0) among patients treated with BEP alone, 2.0 (95% CI 1.4e2.8) among patients treated with BEP with post-chemotherapy surgery, 1.6 (95% CI 1.0e2.5) in the RT group and 4.8 (95% CI 2.8e8.4) in the MTOL group.
DISCUSSION
To our knowledge this is the largest study evaluating sexual function in TCSs with the longest followup ever reported. We found a significantly increased risk of erectile dysfunction in TCSs treated with BEP, RT and MTOL compared to TC survivors who had been followed on a surveillance program. The risk of orgasmic dysfunction was increased in all treatment groups except in TCSs who had been treated with BEP alone. Symptoms of anxiety and depression as well as neurotoxicity were negatively associated with all aspects of sexual function.
The observed increased risk of erectile dysfunction in TC survivors treated with BEP alone or BEP with post-chemotherapy surgery is in contrast to the majority of studies evaluating sexual function in TC survivors. 3, 4, 17, 18 In the 2 studies in which an association was reported cisplatin induced neurotoxicity and endothelial dysfunction were suggested as possible mechanisms. 3, 19 Our results support that cisplatin induced neurotoxicity may be a mediator of the increased risk of erectile dysfunction in long-term TC survivors.
The observed association of BEP and RT with orgasmic dysfunction lost statistical significance after adjusting for neurotoxicity. Thus, it appears that some of the treatment effect is mediated through treatment associated neurotoxicity. A linkage between cisplatin based chemotherapy (alone and with post-chemotherapy surgery) and orgasmic dysfunction was reported in 2 Dutch cross-sectional studies with 215 and 264 patients with TC, respectively, and a followup of approximately 7 years 19, 20 as well as in a Norwegian study of 343 TC survivors treated with cisplatin based chemotherapy with a median followup of 11 years. 3 In the current series the association between BEP and orgasmic dysfunction was observed in patients who had received post-chemotherapy surgery only. This suggests that surgical damage to the sympathetic nerves resulting in retrograde ejaculation and not BEP itself is the most important cause of orgasmic dysfunction among these patients.
The observed increased risk of orgasmic and erectile dysfunction in TC survivors treated with RT is in agreement with a Dutch prospective study in 120 RT treated patients with TC who had symptoms 6 months after TC treatment 21 and with a systematic review of 9 studies with a total of 417 RT treated patients with TC, which demonstrated an increased risk of erectile dysfunction compared to surveillance. 22 In contrast, 2 studies in 47 and 497 RT treated patients, respectively, showed no association with orgasmic and erectile dysfunction. These conflicting findings might be explained by differences in the radiation doses applied and differences in the questionnaires used to assess sexual dysfunction. We suggest that the mechanism of RT causing erectile dysfunction may be vascular damage in the radiation field, resulting in decreased penile blood flow. 23 A probable explanation of orgasmic dysfunction reported in the current study might be neuronal damage in the radiation field.
Orgasmic function and erectile function are considered more physiological aspects of sexual function while sexual desire and sexual satisfaction have a more psychological character. 22 We did not find evidence of decreased sexual desire and decreased intercourse satisfaction with increasing treatment intensity. This suggests that sexual dysfunction in long-term TC survivors is caused by physiological rather than psychological mechanisms. This is in conflict with the conclusions of a Dutch study of 337 TCSs in whom sexual function was assessed by a nonvalidated questionnaire after 7 years of followup. 20 It also conflicts with a Danish study in 401 TCSs with 3 years of followup in whom sexual function was assessed by 6 questions addressing sexual function from the EORTC (European Organization for Research and Treatment of Cancer) QLQ-PR25 (Quality of Life QuestionnaireProstate 25) after a minimum of 3 years of followup. 4 As we used validated questionnaires to assess sexual function and psychological factors (anxiety and depression), we are convinced that psychological factors cannot explain the increased risk of erectile dysfunction and orgasmic dysfunction in TC survivors treated for disseminated disease.
Another possible mechanism explaining sexual dysfunction might be testosterone deficiency, which would be expected to be associated with erectile dysfunction and decreased sexual desire. 24 In the current study we had information on the proportion of TC survivors receiving testosterone substitution. However, we did not have information on the actual serum levels of testosterone and, thus, we could not investigate the association between testosterone deficiency and sexual dysfunction in a meaningful manner.
TC survivors who had been treated with RT, BEP with post-chemotherapy surgery and MTOL were more likely to report that TC treatment had a negative impact on sexual function than TC survivors who had been treated with orchiectomy alone. This illustrates how additional TC treatment probably influences sexual life even years after finalizing the planned treatment.
Contributing to the strengths of this study are the large sample size, the population based and nationwide design, the long-term followup, accurate information on treatment and the use of validated questionnaire measures of sexual function.
It is a limitation that we applied a cross-sectional design as we could not detect a causal inference. However, as the allocation to different treatment modalities was largely unbiased, we are convinced that the differences between the treatment groups represent a true treatment effect.
Another important limitation is the lack of a control group from the Danish background population to compare sexual function in TC survivors to that in healthy, age matched men. However, IIEF-15 has not been validated in a large cohort of healthy men and the primary aim of the current study was to evaluate the effect of different treatment modalities internally. In a Norwegian study evaluating sexual function in 1,084 long-term TCS (104 TCS with surveillance alone) using the BSFI (Brief Male Sexual Function Inventory) the investigators did not report an increased risk of sexual dysfunction apart from the increased risk of orgasmic dysfunction compared to 929 healthy, age matched men from the background population. 3 We are convinced that our reference group of approximately 1,000 TC survivors treated with unilateral orchiectomy and followed on a surveillance program was appropriate to estimate the effect of different treatment modalities.
CONCLUSIONS
The majority of TC survivors had normal erectile function, although treatment with BEP, RT and MTOL was associated with an increased risk of erectile dysfunction in long-term TC survivors compared to patients with TC who underwent surveillance only. The association was partly explained by treatment induced neurotoxicity. Treatment modality was not associated with decreased sexual desire and decreased intercourse satisfaction. As part of the treatment information and consent patients with TC can be reassured about a good chance of long-term normal erectile function except in those who cannot be cured by surgery alone. Especially patients who receive several treatment lines experience erectile and orgasmic dysfunction. Sexual counseling may benefit the increasing group of longterm cancer survivors.
